TCR

Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma 2:30
Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma
Angela Krackhard • 6 Apr 2022
Developing individualized cancer therapies with neoantigen-specific TCRs 4:27
Developing individualized cancer therapies with neoantigen-specific TCRs
Angela Krackhard • 6 Apr 2022
Improving immune-imaging tools to assess cancer immunotherapies 5:33
Improving immune-imaging tools to assess cancer immunotherapies
Angela Krackhard • 6 Apr 2022
Targeting WT1 peptides for TCR-based AML therapy 2:04
Targeting WT1 peptides for TCR-based AML therapy
Chiara Bonini • 1 Apr 2022
TCR redirected T cells for cancer therapy 1:46
TCR redirected T cells for cancer therapy
Chiara Bonini • 1 Apr 2022
The use of CRISPR-Cas9 technology in the development of T cell therapies 0:55
The use of CRISPR-Cas9 technology in the development of T cell therapies
Alessio Nahmad • 31 Mar 2022
Accelerating the identification of clinically relevant T cell therapies 2:17
Accelerating the identification of clinically relevant T cell therapies
Elvira D’Ippolito • 31 Mar 2022
Genome editing to address challenges with adoptive T-cell therapy 3:02
Genome editing to address challenges with adoptive T-cell therapy
Chiara Bonini • 22 Nov 2021
miCAR: combining microRNA gene silencing with CAR expression 4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
Selecting TCRs: understanding peptide-HLA-TCR interactions 6:05
Selecting TCRs: understanding peptide-HLA-TCR interactions
Dolores Schendel • 25 Feb 2021
How the TCR field can learn from CARs 3:23
How the TCR field can learn from CARs
Dolores Schendel • 25 Feb 2021
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors 5:11
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors
Dolores Schendel • 25 Feb 2021
CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate 1:48
CAR-TCR Europe highlights: synthetic biology & the autologous vs allogeneic debate
Dalip Sethi • 23 Feb 2021
The content of VJRegenMed is intended for healthcare professionals